3D Medicines, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: KYG8872R1011

HKD

5.05

0.05 (1.0%)

Dec 12

HKG

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Consun Pharmaceutical Group Ltd.

Tong Ren Tang Technologies Co., Ltd.

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Ocumension Therapeutics

Shanghai Junshi Biosciences Co., Ltd.

CARsgen Therapeutics Holdings Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Cutia Therapeutics

Lepu Biopharma Co., Ltd.

3D Medicines, Inc.

Why is 3D Medicines, Inc. ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Poor long term growth as Operating profit has grown by an annual rate 32.79% of over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Flat results in Jun 24

NO KEY NEGATIVE TRIGGERS

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 44.29%, its profits have fallen by -37%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is 3D Medicines, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

3D Medicines, Inc.

44.29%

-0.23

71.18%

Hang Seng Hong Kong

27.36%

1.06

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-13.61%

EBIT Growth (5y)

32.79%

EBIT to Interest (avg)

-32.72

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.78

Sales to Capital Employed (avg)

42.08

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.51

EV to EBIT

-13.91

EV to EBITDA

-18.88

EV to Capital Employed

7.83

EV to Sales

2.99

PEG Ratio

Dividend Yield

ROCE (Latest)

-56.32%

ROE (Latest)

-27.50%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for 3D Medicines, Inc.

Depreciation

At HKD 16.84 MM has Grown at 40.32%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)